Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Melanoma 44Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 14Lung Neoplasms 11Neoplasm Metastasis 10Pancreatic Neoplasms 9Brain Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 6Skin Neoplasms 5Colonic Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Breast Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Skin Diseases 2Recurrence 2Neurofibromatosis 1 2Lymphoma 2Leukemia, Hairy Cell 2Hereditary Sensory and Autonomic Neuropathies 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2

Interventions

Imatinib Mesylate 67Sunitinib 27nilotinib 14regorafenib 13ripretinib 10avapritinib 5Ipilimumab 5Dasatinib 5spartalizumab 4Laparoscopy 4CTLA-4 Antigen 44-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4pexidartinib 3pazopanib 3binimetinib 3Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Midazolam 3Leucovorin 3Gemcitabine 3Bevacizumab 3trametinib 2tanespimycin 2ponatinib 2pembrolizumab 2masitinib 2famitinib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Stromal Tumors × binimetinib × Clear all
NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
75 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05080621 2022-01-05

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Deciphera Pharmaceuticals, LLC

Phase 1/2 Withdrawn
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03158103 2021-04-30

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
3 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡